The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 11 of the 70 sources its claims cite were checked for support.
Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse
Open accessAbstract
The Rb/p16(Ink4a) and p53/p19Arf tumor suppressor pathways have been linked to diverse cancer-relevant processes, including those governing the cellular responses to telomere dysfunction. In this study, we sought to provide direct genetic evidence of a role for the Ink4a/Arf tumor suppressor gene, encoding both p16(Ink4a) and p19(Arf), in modulating the cellular and tissue phenotypes associated with telomere dysfunction by using the mTerc Ink4a/Arf mouse model. In contrast to the rescue associated with p53 deficiency, Ink4a/Arf deficiency did not attenuate the degenerative phenotypes elicited by telomere dysfunction in the late-generation mTerc-/- mice. Furthermore, in contrast to accelerated cancer onset and increased epithelial cancers of late-generation mTerc-/- p53 mutant mice, late-generation mTerc-/- Ink4a/Arf mutant mice experienced a delayed tumor onset and maintained the lymphoma and sarcoma spectrum. Consistent with the negligible role of Ink4a/Arf in the telomere checkpoint response in vivo, late-generation mTerc-/- Ink4a/Arf-/- tissues show activated p53, and derivative tumor cell lines sustain frequent loss of p53 function, whereas all early generation mTerc Ink4a/Arf-/- tumor cell lines remain intact for p53. In addition, the late-generation mTerc-/- Ink4a/Arf-/- tumors showed activation of the alternative lengthening of telomere mechanism, underscoring the need for adaptation to the presence of telomere dysfunction in the absence of p16(Ink4a) and p19(Arf). These observations highlight the importance of genetic context in dictating whether telomere dysfunction promotes or suppresses age-related degenerative conditions as well as the rate of initiation and type of spontaneous cancers.
Overview
CoChat Summary
## TL;DR
Using a telomerase-deficient mouse model crossed with Ink4a/Arf mutants, the study finds that loss of p16Ink4a/p19Arf does not change the degenerative phenotypes caused by telomere dysfunction and does not alter the tumor spectrum. Instead, telomere dysfunction still activates p53, delays tumor onset, and in late tumors selects for p53 pathway defects and ALT activation.
## Key findings
- In late-generation mTerc-/- mice, the anaphase bridge index (ABI) was comparable across all three Ink4a/Arf genotypes, indicating Ink4a/Arf status does not influence the degree of telomere dysfunction.
- Late-generation mTerc-/-Ink4a/Arf+/- mice showed tumor death dropping from 84% to 20% and tumor-free latency increasing from 71.6 to 104.9 weeks; late-generation mTerc-/-Ink4a/Arf-/- mice showed tumor death dropping from 98% to 43% and latency increasing from 38.6 to 65.3 weeks.
- The tumor spectrum did not change with telomere dysfunction: for Ink4a/Arf+/- mice, histiocytic sarcomas/soft tissue sarcomas/lymphomas were 35%/30%/19% in early generations versus 39%/23%/23% in late generations; for Ink4a/Arf-/- mice, the corresponding values were 57%/24%/11% versus 59%/28%/10%.
- Late-generation mTerc-/-Ink4a/Arf-/- tumors frequently showed compromised p53 checkpoint responses to doxorubicin (6 of 10 cultures) and telomere changes consistent with ALT, including heterogeneous telomeres and signal-free ends rising from 0.9% to 8.7–9.3%.
## Methods
- Genetic mouse study comparing early- and late-generation mTerc mice with different Ink4a/Arf genotypes; spontaneous tumors and degenerative phenotypes were assessed in vivo.
- Analyses included ABI measurements in GI crypts, histology, apoptosis and p53 immunohistochemistry, tumor latency/incidence by Kaplan-Meier and log-rank test, and telomere assays (qFISH, telomere repeat fragment Southern).
- Functional follow-up used cultured tumor cell lines, MEFs, and astrocytes, including doxorubicin-induced p53 checkpoint assays, p53 sequencing, western blotting, and 3T3 growth assays.
## Limitations
- The paper itself notes that comparisons with prior mTerc-/-p53-/- studies are difficult because those studies used carcinogens and did not analyze normal aging tissues; this limits direct cross-model inference.
- The text makes evident that the conclusions are based on a mouse model and the tissues/cancer types examined here, so generalization to other genetic contexts or human cancers is not directly tested in this paper.
- The text also makes evident that some assays used relatively small sample sizes for specific analyses (for example, n=4–7 per group for ABI/apoptosis measurements), which may limit precision in those comparisons.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
11 Valid · 0 Not valid · 28 Not checked · 62 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with previous reports (27), G4 mTerc -/ -Ink4a / Arf -/ -MEFs showed an intermediate phenotype of decreased growth rates after 10 population doublings with steady slow proliferation thereafter, indicating that telomere dysfunction suppresses the growth rate, but not the immortalization potential, of Ink4a / Arf -/ -MEFs.”
What the sources say
- Partly supportedcites [27] Smogorzewska A, de Lange T (2002) EMBO J 21:4338-4348. ∣ p53 Mutational Analysis. DNA was isolated from frozen tumor tissue, and the p53 gene was sequenced as described (54). Statistical Analysis. Statistical analyses were done by using GraphPad Prism 4 (GraphPadSoftware, San Diego, CA). Tumor incidence was plotted by using the Kaplan-Meier analysis. Only animals possessing histologically verified cancer were scored as an event. Statistical significance was measured by using the log-rank test. Wethank S. Artandi, N. Sharpless, S. Chang, and members of the R.A.D. laboratory for helpful discussi sourceExperimental — accuracy not yet measured
The “Mouse telomere damage signaling: p53 alone” section says Ink4a/Arf-deficient cells can continue growing despite telomere dysfunction and that shortened telomeres did not prevent immortalization of late-generation mTerc-deficient MEFs. It does not report growth rates for G4 mTerc−/− Ink4a/Arf−/− MEFs, a decline after 10 population doublings, or steady slow proliferation thereafter. Page numbers were not available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Doxorubicin treatment of early passage tumor cell lines revealed that five of five early generation mTerc Ink4a / Arf -/ -tumors maintained intact p53 response evidenced by p53 Ser-18 phosphorylation (37, 38) and associated induction of p21 CIP1 .”
What the sources say
- Not checked — no full text of the sourcecites [37] Shieh SY, Ikeda M, Taya Y, Prives C (1997) Cell 91:325-334. source
- Partly supportedcites [38] Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB (1997) Genes Dev 11:3471-3481. sourceExperimental — accuracy not yet measured
The paper’s ‘Ionizing irradiation induces phosphorylation of p53 on serine-15’ section reports DNA-damage-induced phosphorylation of human p53; its introductory discussion identifies human Ser-15 as corresponding to mouse Ser-18. It also reports p21 induction after irradiation. It does not establish Ser-18 phosphorylation after doxorubicin in the specified mouse tumor lines; the five-of-five observation is the citing authors’ own result, not a finding of this source. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Both processes would function to impede the accumulation of a greater number of somatic mutations thought to be required for the development of epithelial cancers (50, 51).”
What the sources say
- Supportedcites [50] Armitage P, Doll R (1954) Br J Cancer 8:1-12. source
The discussion around Table I (p. 4) says the cancer data accord with a theory requiring six or seven successive cellular changes before cancer appears. The paper also calls these changes mutations (p. 2). The claim presents impediment by “both processes” as the citing authors’ inference, rather than a finding attributed to this source. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [51] DePinho RA (2000) Nature 408:248-254. source
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, the activation of ALT in tumors with telomere dysfunction may serve as another avenue toward alleviating the antitumorigenic effects of telomere dysfunction, as we have observed previously in murine cell-based transformation systems (52).”
What the sources say
- Supportedcites [52] Chang S, Khoo CM, Naylor ML, Maser RS, DePinho RA (2003) Genes Dev 17:88-100. source
The Discussion (page unavailable) reports that ALT activation lengthened telomeres and enhanced tumor growth in transformed mouse-cell lines. The results section also states that ALT enhanced their in vitro growth and subcutaneous tumor potential, supporting the claim’s qualified wording. The paper distinguishes this benefit from metastatic progression, which ALT did not restore. (LLM, conf=0.91)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was the expected ABI increase in the late-generation G4/G5 mTerc -/ -intestinal crypts compared with the early generation mTerc + / + , + / -, and G1 mTerc -/ -controls (referred to as early generation mTerc from this point onward) (Fig. 1 A ).”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
47 more claims
Create a free account to see all 101 claims and to verify the 4 references still open.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 33
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“however, in the setting of telomere dysfunction, G4/G5 TERCÀ/À Ink4a/ArfÀ/À mice show reduced tumor incidence and increased latency (87,88) and no change in the tumor spectrum.”
From Telomeres and telomerase in cancer (2010) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Telomere Dysfunction Impedes Tumorigenesis in Ink4a/Arf Mutant Mice and Has No Impact on the Ink4a/Arf Mutant Tumor Spectrum.
“Mean TFU and percent signal-free ends were 103.46, 181.94, and 141.96, and 0.9, 9.3, and 8.7%, respectively.”
§ Telomere Dysfunction Impedes Tumorigenesis in Ink4a/Arf Mutant Mice and Has No Impact on the Ink4a/Arf Mutant Tumor Spectrum.
“Arf -/ -tumor cell lines also have mean telomere lengths [181.84 and 141.96 telomere fluorescence units (TFUs)] that are comparable in length to the early generation tumor mTerc Ink4a / Arf -/ -cells (103.46 TFUs),”
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
A DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917
A survey of telomerase activity in human cancer
Shay, J. W., & Bacchetti, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00062-2 · Cited by 2,794
Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues
Jaffe, E. S. (2003) · Cited by 2,141
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Self-citationTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis
Armitage, P., & Doll, R. (1954) · British Journal of Cancer · doi:10.1038/bjc.1954.1 · Cited by 1,549
Research works printed but not linked: 2
- L Qi, MA Strong, BO Karim, M Armanios, DL Huso, CW Greider Cancer Res 63, 8188–8196 (2003).
- T Kamijo, E van de Kamp, MJ Chong, F Zindy, JA Diehl, CJ Sherr, PJ McKinnon Cancer Res 59, 2464–2469 (1999).
Cited by
Telomeres and telomerase in cancer
Artandi, S. E., & DePinho, R. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp268 · Cited by 823
Self-citationLinking functional decline of telomeres, mitochondria and stem cells during ageing
Sahin, E., & DePinho, R. A. (2010) · Nature · doi:10.1038/nature08982 · Cited by 759
Self-citationTelomere length, stem cells and aging
Blasco, M. A. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.38 · Cited by 747
Telomerase and cancer therapeutics
Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728
Genetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
“…p53 mutant mice develop epithelial cancers, including CRC, whereas telomere-dysfunctional Ink4a/Arf-/- mice do not, underscoring the role of p53-dependentDNAdamage signaling in dictating whether telomere dysfunction can serve as a mutational mechanism driving carcinomas (Khoo et al. 2007).”
BackgroundSelf-citation
Metadata
- Authors
- Khoo, C. M., Carrasco, D. R., Bosenberg, M. W., Paik, J.-H., & DePinho, R. A.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- University of Vermont (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2007-03-06
- Volume
- 104
- Issue
- 10
- Pages
- 3931-3936
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC1820686
- OpenAlex
- W2143285081
- Semantic Scholar
- b98b642663ef791b4d970039338d8aae324241d2
- Cited by
- 52
- References
- 57
- Citations by year
- 2025: 1 · 2024: 2 · 2022: 1 · 2021: 3 · 2020: 1 · 2018: 3 · 2017: 4 · 2016: 2 · 2015: 2 · 2014: 5 · 2013: 3 · 2012: 5
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Ellison Medical Foundation
- Damon Runyon Cancer Research Foundation
- Sidney Kimmel Foundation for Cancer Research
- Sidney Kimmel Foundation
- National Institutes of Health
- National Cancer Institute (U01CA084313, R01CA084628)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- p16INK4a, p19ARF, telomere dysfunction, p53, alternative lengthening of telomeres, lymphoma, sarcoma, age-related degeneration
- MeSH terms
- Animals, Mice, Transgenic, Neoplasms, Neoplasms, Glandular and Epithelial, Phenotype, Time Factors, Genes, Tumor Suppressor, Genes, p53, Tumor Suppressor Protein p53, 3T3 Cells, Telomere, In Situ Hybridization, Fluorescence, Telomerase, Cyclin-Dependent Kinase Inhibitor p16, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. https://app.cochat.ai/papers/10.1073/pnas.0700093104
- The paper
- Khoo, C. M., Carrasco, D. R., Bosenberg, M. W., Paik, J.-H., & DePinho, R. A. (2007). Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0700093104
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.